 - Patients must have newly diagnosed T-ALL or T-lineage lymphoblastic lymphoma T-NHL stage II-IV; B-lineage lymphoblastic lymphoma will not be eligible for this study; a diagnosis of T-ALL is established when leukemic blasts lack myeloperoxidase or evidence of B-lineage derivation cluster of differentiation CD19CD22CD20, and express either surface or cytoplasmic CD3 or two or more of the antigens CD8, CD7, CD5, CD4, CD2 or CD1a; if surface CD3 is expressed on all leukemic cells, additional markers of immaturity, including transmission disequilibrium test TdT, CD34 or CD99 will be assessed for expression; cases with uncertain expression will receive additional review within the appropriate Childrens Oncology Group COG reference laboratory 